Human TLR2 Stable Cell Line - BaF3

The Human TLR2 gene, also known as CD282 or TIL4, is located on chromosome 4q31.3 and encodes a transmembrane protein belonging to the Toll-like receptor family. This receptor plays a critical role in recognizing pathogen-associated molecular patterns (PAMPs) derived from bacteria, fungi, and viruses. TLR2 functions primarily by forming heterodimers with either TLR1 or TLR6, allowing it to detect a broad range of microbial ligands, including bacterial lipoproteins, peptidoglycan, and lipoteichoic acid. Upon ligand binding, the receptor triggers downstream signaling cascades via the MyD88-dependent pathway, ultimately activating NF-κB and leading to the production of pro-inflammatory cytokines. The Human TLR2 Stable Cell Line - BaF3 is generated by stably expressing the full-length human TLR2 gene in the murine BaF3 pro-B cell line. These cells are IL-3 dependent and have been engineered to respond specifically to human TLR2 stimulation, making them a clean and reproducible system for studying receptor function in a controlled background.

This cell line is widely used in immunology and drug discovery research. It provides a reliable platform for screening and characterizing TLR2-specific agonists and antagonists, evaluating the immunomodulatory properties of novel compounds, and studying the mechanisms underlying TLR2-mediated inflammatory responses. Because the BaF3 parental line lacks endogenous TLR expression, the engineered line offers minimal background noise, making it ideal for high-throughput screening assays. Researchers also use these cells to investigate how TLR2 recognizes structurally diverse microbial components and to examine the receptor’s role in autoimmune diseases, infectious diseases, and vaccine adjuvant development. The ability to induce a measurable, dose-dependent response to known TLR2 ligands such as Pam3CSK4 and Pam2CSK4 makes this cell line a valuable tool for functional studies, ligand specificity testing, and the preclinical evaluation of therapeutic candidates targeting TLR2 signaling pathways.